Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders
暂无分享,去创建一个
M. Leboyer | J. Os | J. Honnorat | B. Rutten | J. Stevens | P. Molenaar | M. Losen | P. Martinez-Martinez | R. Tamouza | A. Szoke | M. Baets
[1] D. Manahan‐Vaughan,et al. Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis , 2013, Neuropharmacology.
[2] M. Daly,et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis , 2013, The Lancet.
[3] M. Skalej,et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. , 2013, JAMA psychiatry.
[4] J. Dalmau,et al. Paraneoplastic neurological syndromes. , 1988, Cancer Investigation.
[5] K. Berman,et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. , 2012, The American journal of psychiatry.
[6] N. Fineberg,et al. Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. , 2012, The British journal of psychiatry : the journal of mental science.
[7] J. Verschuuren,et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. , 2012, Brain : a journal of neurology.
[8] I. Rosenzweig,et al. Abnormalities in thalamic neurophysiology in schizophrenia: Could psychosis be a result of potassium channel dysfunction? , 2012, Neuroscience & Biobehavioral Reviews.
[9] S. J. James,et al. Cerebral folate receptor autoantibodies in autism spectrum disorder , 2012, Molecular Psychiatry.
[10] B. Crespi,et al. Comparative immunogenetics of autism and schizophrenia , 2011, Genes, brain, and behavior.
[11] C A Jones,et al. Animal models of schizophrenia , 2011, British journal of pharmacology.
[12] Christian G Bien,et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges , 2011, The Lancet Neurology.
[13] Jim van Os,et al. Late onset autism and anti-NMDA-receptor encephalitis , 2011, The Lancet.
[14] J. Schott,et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis , 2011, Annals of neurology.
[15] L. Crepaldi,et al. Altered levels of glutamatergic receptors and Na+/K+ ATPase-α1 in the prefrontal cortex of subjects with schizophrenia , 2011, Schizophrenia Research.
[16] R. Balice-Gordon,et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.
[17] U. Hegerl,et al. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings , 2011, Psychopharmacology.
[18] Jim van Os,et al. The environment and schizophrenia , 2010, Nature.
[19] Peter B. Jones,et al. Disease-relevant autoantibodies in first episode schizophrenia , 2010, Journal of Neurology.
[20] L. Ptáček,et al. Episodic Neurological Channelopathies , 2010, Neuron.
[21] R. Balice-Gordon,et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series , 2010, The Lancet Neurology.
[22] A. Gomez,et al. Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction , 2010, Autoimmunity.
[23] A. Vincent,et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.
[24] S. Cannon. Voltage‐sensor mutations in channelopathies of skeletal muscle , 2010, The Journal of physiology.
[25] D. Kullmann,et al. Neurological channelopathies: new insights into disease mechanisms and ion channel function , 2010, The Journal of physiology.
[26] M. Hanna,et al. Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? , 2010, The Journal of physiology.
[27] A. Vincent,et al. Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems , 2010, Journal of Clinical Immunology.
[28] J. Dalmau,et al. Antibodies and neuronal autoimmune disorders of the CNS , 2010, Journal of Neurology.
[29] F. Lehmann-Horn,et al. Sodium channelopathies of skeletal muscle result from gain or loss of function , 2010, Pflügers Archiv - European Journal of Physiology.
[30] M. Mühlethaler,et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. , 2010, The Journal of clinical investigation.
[31] L. Ptáček,et al. Mutations in Potassium Channel Kir2.6 Cause Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis , 2010, Cell.
[32] Glinda S Cooper,et al. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. , 2009, Journal of autoimmunity.
[33] A. Vincent,et al. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. , 2009, The American journal of pathology.
[34] P. Striano,et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients , 2009, Journal of Neuroimmunology.
[35] D. Bonifati,et al. AChR deficiency due to ε-subunit mutations: two common mutations in the Netherlands , 2009, Journal of Neurology.
[36] B. Volpe,et al. Losing your nerves? Maybe it's the antibodies , 2009, Nature Reviews Immunology.
[37] A. Vincent,et al. Autoimmune disorders of the neuromuscular junction. , 2008, Neurology India.
[38] Michelle J Chandley,et al. Increased antibodies for the α7 subunit of the nicotinic receptor in schizophrenia , 2009, Schizophrenia Research.
[39] Michael K. Hutchinson,et al. PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY , 2008, Neurology.
[40] David G. Amaral,et al. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism , 2008, Brain, Behavior, and Immunity.
[41] O. Gervásio,et al. Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction , 2008, Annals of neurology.
[42] N. Blau,et al. Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. , 2007, Neuropediatrics.
[43] B. Fontaine,et al. Hypokalemic periodic paralysis: A model for a clinical and research approach to a rare disorder , 2007, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
[44] J. Chapman,et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. , 2007, Arthritis and rheumatism.
[45] B. Volpe,et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.
[46] Karl J. Friston,et al. Synaptic Plasticity and Dysconnection in Schizophrenia , 2006, Biological Psychiatry.
[47] T. Yoshio,et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. , 2006, Arthritis and rheumatism.
[48] A. Vincent,et al. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis , 2005, Current opinion in neurology.
[49] Nenad Blau,et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. , 2005, The New England journal of medicine.
[50] R. Jonsson,et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors , 2005, European journal of neurology.
[51] Masahiko Watanabe,et al. NR2 to NR3B subunit switchover of NMDA receptors in early postnatal motoneurons , 2005, The European journal of neuroscience.
[52] Ichiro Nakashima,et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.
[53] F. Lehmann-Horn,et al. Electrophysiology and molecular pharmacology of muscle channelopathies. , 2004, Revue neurologique.
[54] R. Gómez,et al. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera , 2004, Glia.
[55] A. Vincent,et al. Antibodies in Myasthenia Gravis and Related Disorders , 2003, Annals of the New York Academy of Sciences.
[56] L. Phillips. The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.
[57] A. Blamire,et al. Maternal neuronal antibodies associated with autism and a language disorder , 2003, Annals of neurology.
[58] H. Johansen-Berg,et al. Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy , 2002, Journal of Neuroimmunology.
[59] M. Pusch. Myotonia caused by mutations in the muscle chloride channel gene CLCN1 , 2002, Human mutation.
[60] R. Gómez,et al. Antibodies Against Cerebral M1 Cholinergic Muscarinic Receptor from Schizophrenic Patients: Molecular Interaction1 , 2002, The Journal of Immunology.
[61] B. Diamond,et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus , 2001, Nature Medicine.
[62] K. Ohno,et al. Congenital myasthenic syndromes: recent advances. , 1999, Archives of neurology.
[63] F. Lehmann-Horn,et al. Voltage-gated ion channels and hereditary disease. , 1999, Physiological reviews.
[64] J. Wokke,et al. Acquired slow–channel syndrome: A form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel , 1998, Annals of neurology.
[65] A. Vincent,et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. , 1996, The Journal of clinical investigation.
[66] K. Ohno,et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. , 1996, Human molecular genetics.
[67] J. G. van Dijk,et al. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves , 1995, Annals of neurology.
[68] G. L. Curran,et al. Macromolecular permeability across the blood nerve and blood brain barriers Joseph F. Poduslo, Geoffry L. Curran, Carole T. Berg. Molecular Neurobiology Laboratory, Mayo Foundation, Rochester, MN 55905 USA , 1994, Neurobiology of Aging.
[69] B. Sakmann,et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.
[70] V. Singh,et al. Detection of maternal antibodies in infantile autism. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.
[71] C. Hulsebosch,et al. Time course of penetration of xenogeneic IgG into the central nervous system of the neonatal rat: an immunohistochemical and radionuclide tracer study , 1989, Journal of Neuroimmunology.
[72] P. De Camilli,et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. , 1988, The New England journal of medicine.
[73] A. Vincent,et al. The slow channel syndrome. Two new cases. , 1987, Brain : a journal of neurology.
[74] A. Engel,et al. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[75] J. Hammerstad,et al. The origin and turnover rates of cerebrospinal fluid albumin and gamma-globulin in man. , 1970, Journal of the neurological sciences.
[76] H. Lerche,et al. Hereditary channelopathies in neurology. , 2010, Advances in experimental medicine and biology.
[77] J. Stockman. Autoantibodies to Folate Receptors in the Cerebral Folate Deficiency Syndrome , 2007 .
[78] J. Newsom-Davis,et al. Immunopathology of the Lambert-Eaton myasthenic syndrome , 2004, Springer Seminars in Immunopathology.
[79] T. Shike,et al. Animal models. , 2001, Contributions to nephrology.
[80] B. Rabin,et al. Autoimmunity in schizophrenia: a review of recent findings. , 1993, Annals of medicine.
[81] The Environment and , 1992 .
[82] W D Rowe,et al. Identification of risk. , 1986, Progress in clinical and biological research.
[83] Rowe Wd,et al. Identification of risk. , 1986 .